about
Calprotectin and the Magnitude of Antibodies to Infliximab in Clinically-stable Ulcerative Colitis Patients are More Relevant Than Infliximab Trough Levels and Pharmacokinetics for Therapeutic Escalation.Clinical performance of an infliximab rapid quantification assay.Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassaysAnti-TNF treatment in Crohn's disease and risk of bowel resection-a population based cohort study.Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays.The performance of Remicade®-optimized quantification assays in the assessment of Flixabi® levels
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Optimizing biological therapy in Crohn's disease.
@en
type
label
Optimizing biological therapy in Crohn's disease.
@en
prefLabel
Optimizing biological therapy in Crohn's disease.
@en
P2093
P2860
P1476
Optimizing biological therapy in Crohn's disease.
@en
P2093
Krisztina Barbara Gecse
Péter László Lakatos
Zsuzsanna Végh
P2860
P356
10.1586/17474124.2016.1096198
P577
2015-10-16T00:00:00Z